Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 2
2002 1
2003 2
2004 8
2005 9
2006 10
2007 11
2008 11
2009 20
2010 18
2011 15
2012 19
2013 17
2014 22
2015 19
2016 19
2017 28
2018 16
2019 7
2020 9
2021 6
2022 3
2023 1
2024 3
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Results by year

Filters applied: . Clear all
Page 1
A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
Gubelin Harcha W, Barboza Martínez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, Barnes A, Ferron-Brady G, Chetty D. Gubelin Harcha W, et al. J Am Acad Dermatol. 2014 Mar;70(3):489-498.e3. doi: 10.1016/j.jaad.2013.10.049. Epub 2014 Jan 9. J Am Acad Dermatol. 2014. PMID: 24411083 Clinical Trial.
Hair count and width increased dose dependently with dutasteride. Dutasteride 0.5 mg significantly increased hair count and width in a 2.54-cm diameter and improved hair growth (frontal view; panel photographic assessment) at week 24 compared with finasteride (P = . …
Hair count and width increased dose dependently with dutasteride. Dutasteride 0.5 mg significantly increased hair count and wi …
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group. Roehrborn CG, et al. Eur Urol. 2010 Jan;57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19. Eur Urol. 2010. PMID: 19825505 Clinical Trial.
INTERVENTION: Oral daily tamsulosin, 0.4 mg; dutasteride, 0.5 mg; or a combination of both. MEASUREMENTS: The 4-yr primary end point was time to first AUR or BPH-related surgery. ...CONCLUSIONS: The 4-yr CombAT data provide support for the long-term use of dutasteride …
INTERVENTION: Oral daily tamsulosin, 0.4 mg; dutasteride, 0.5 mg; or a combination of both. MEASUREMENTS: The 4-yr primary end point …
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS; Dutasteride Alopecia Research Team. Olsen EA, et al. J Am Acad Dermatol. 2006 Dec;55(6):1014-23. doi: 10.1016/j.jaad.2006.05.007. J Am Acad Dermatol. 2006. PMID: 17110217 Clinical Trial.
RESULTS: Dutasteride increased target area hair count versus placebo in a dose-dependent fashion and dutasteride 2.5 mg was superior to finasteride at 12 and 24 weeks. ...Scalp and serum dihydrotestosterone levels decreased, and testosterone levels increased, in a d …
RESULTS: Dutasteride increased target area hair count versus placebo in a dose-dependent fashion and dutasteride 2.5 mg was su …
Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo-controlled study.
Sánchez-Meza E, Ocampo-Candiani J, Gómez-Flores M, Herz-Ruelas ME, Ocampo-Garza J, Orizaga-Y-Quiroga TL, Martínez-Moreno A, Ocampo-Garza SS. Sánchez-Meza E, et al. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e806-e808. doi: 10.1111/jdv.18285. Epub 2022 Jun 16. J Eur Acad Dermatol Venereol. 2022. PMID: 35648446 Clinical Trial. No abstract available.
Randomized Placebo-Controlled Clinical Trial of Dutasteride for Reducing Heavy Drinking in Men.
Covault J, Tennen H, Feinn R. Covault J, et al. J Clin Psychopharmacol. 2024 May-Jun 01;44(3):223-231. doi: 10.1097/JCP.0000000000001849. J Clin Psychopharmacol. 2024. PMID: 38684046 Free PMC article. Clinical Trial.
Sensitivity analysis identified baseline drinking to cope as a factor associated with larger reductions in drinking for dutasteride compared with placebo-treated participants. Dutasteride was well tolerated. Adverse events more common in the dutasteride group …
Sensitivity analysis identified baseline drinking to cope as a factor associated with larger reductions in drinking for dutasteride c …
A Phase II Trial of Abiraterone With Dutasteride for Second-Generation Antiandrogen- and Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer.
Shiota M, Inoue R, Tashiro K, Kobayashi K, Horiyama S, Kanji H, Eto M, Egawa S, Haginaka J, Matsuyama H. Shiota M, et al. J Clin Pharmacol. 2023 Apr;63(4):445-454. doi: 10.1002/jcph.2191. Epub 2023 Jan 17. J Clin Pharmacol. 2023. PMID: 36484758 Clinical Trial.
This study aimed to evaluate the efficacy and safety of adding 5alpha-reductase inhibitor dutasteride to abiraterone, explore proof of concept, and identify candidates suitable for combination therapy. ...No patients experienced grade 3 adverse events. Although dutaster …
This study aimed to evaluate the efficacy and safety of adding 5alpha-reductase inhibitor dutasteride to abiraterone, explore proof o …
Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP. Roehrborn CG, et al. BJU Int. 2011 Mar;107(6):946-54. doi: 10.1111/j.1464-410X.2011.10124.x. Epub 2011 Feb 18. BJU Int. 2011. PMID: 21332630 Clinical Trial.
Eligible patients received tamsulosin 0.4 mg, dutasteride 0.5 mg, or a combination of both. The primary endpoint was time to first AUR or BPH-related surgery. ...These analyses support the long-term use of combined therapy with dutasteride plus tamsulosin in men wit …
Eligible patients received tamsulosin 0.4 mg, dutasteride 0.5 mg, or a combination of both. The primary endpoint was time to first AU …
The 'Prostate Embolisation AS first-line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial' (P-EASY ADVANCE): a randomised controlled trial of prostate embolisation vs medication for BPH.
Brown N, Kiosoglous A, Castree S, Firouzmand S, McBean R, Walker DG, Wallace S, Kua B, Gianduzzo T, Esler RC, Campbell P, Schoeman J, Yaxley J. Brown N, et al. BJU Int. 2024 Dec;134 Suppl 2(Suppl 2):38-46. doi: 10.1111/bju.16479. Epub 2024 Aug 13. BJU Int. 2024. PMID: 39139009 Free PMC article. Clinical Trial.
OBJECTIVE: To compare prostate artery embolisation (PAE) to the combination of tamsulosin and dutasteride therapy as a potential first-line therapy for obstructive benign prostatic hyperplasia (BPH) in treatment-naive patients in the 'Prostate Embolisation AS first-line th …
OBJECTIVE: To compare prostate artery embolisation (PAE) to the combination of tamsulosin and dutasteride therapy as a potential firs …
Neoadjuvant Enzalutamide Prior to Prostatectomy.
Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME. Montgomery B, et al. Clin Cancer Res. 2017 May 1;23(9):2169-2176. doi: 10.1158/1078-0432.CCR-16-1357. Epub 2016 Nov 9. Clin Cancer Res. 2017. PMID: 28151719 Free PMC article. Clinical Trial.
We evaluated neoadjuvant therapy prior to prostatectomy with the potent AR antagonist enzalutamide (enza) either alone or in combination with dutasteride (dut) and leuprolide (enza/dut/luteinizing hormone-releasing hormone analogues [LHRHa]).Experimental Design: Forty-eigh …
We evaluated neoadjuvant therapy prior to prostatectomy with the potent AR antagonist enzalutamide (enza) either alone or in combination wit …
Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer.
Gaudet M, Vigneault É, Foster W, Meyer F, Martin AG. Gaudet M, et al. Radiother Oncol. 2016 Jan;118(1):141-7. doi: 10.1016/j.radonc.2015.11.022. Epub 2015 Dec 15. Radiother Oncol. 2016. PMID: 26702991 Clinical Trial.
OBJECTIVE: To determine the efficacy and toxicity of a 3-month regimen of Dutasteride and Bicalutamide compared to LHRH agonists for prostate volume (PV) reduction prior to permanent implant prostate brachytherapy (PIPB). ...EPIC sexual summary score was significantly bett …
OBJECTIVE: To determine the efficacy and toxicity of a 3-month regimen of Dutasteride and Bicalutamide compared to LHRH agonists for …
222 results